AGÕæÈ˹ٷ½

STOCK TITAN

[SCHEDULE 13G/A] ReShape Lifesciences, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary

ReShape Lifesciences Schedule 13G/A discloses that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri each report beneficial ownership of 80 shares of common stock of the issuer. The 80-share position is described as 8 shares held plus 72 shares issuable on exercise of warrants, and the warrant-related issuable shares are subject to a 9.99% beneficial ownership blocker. The holdings are reported as of June 30, 2025.

The filing uses a class base of 2,385,960 shares (1,331,356 outstanding plus 1,054,604 shares sold in a recent offering) and reports that each reporting person represents 0.003% of the class. The reporting parties include a Cayman Islands fund managed by Ayrton Capital and Waqas Khatri as managing member; signatures certify the securities were acquired and are held in the ordinary course of business and not to change or influence control.

ReShape Lifesciences Schedule 13G/A indica che Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B e Waqas Khatri dichiarano ciascuno una detenzione beneficiaria di 80 azioni del capitale sociale dell'emittente. La posizione di 80 azioni è descritta come 8 azioni detenute ±è¾±Ã¹ 72 azioni emettibili all'esercizio dei warrant, e le azioni emettibili in relazione ai warrant sono soggette a un blocco di partecipazione del 9,99%. Le partecipazioni sono riportate al 30 giugno 2025.

La comunicazione utilizza una base di classe di 2.385.960 azioni (1.331.356 in circolazione ±è¾±Ã¹ 1.054.604 azioni vendute in un'offerta recente) e segnala che ogni soggetto dichiarante rappresenta il 0,003% della classe. Le parti segnalanti includono un fondo delle Isole Cayman gestito da Ayrton Capital e Waqas Khatri in qualità di membro amministratore; le firme certificano che i titoli sono stati acquisiti e sono detenuti nell'ordinario corso dell'attività e non con l'intento di modificare o influenzare il controllo.

ReShape Lifesciences Schedule 13G/A revela que Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B y Waqas Khatri informan cada uno una titularidad beneficiaria de 80 acciones del capital social del emisor. La posición de 80 acciones se describe como 8 acciones en posesión ³¾Ã¡²õ 72 acciones susceptibles de emitirse al ejercerse warrants, y las acciones emitibles vinculadas a los warrants están sujetas a un bloqueo de titularidad beneficiaria del 9,99%. Las tenencias se comunican al 30 de junio de 2025.

La presentación utiliza una base de clase de 2.385.960 acciones (1.331.356 en circulación ³¾Ã¡²õ 1.054.604 acciones vendidas en una oferta reciente) e informa que cada declarante representa el 0,003% de la clase. Las partes informantes incluyen un fondo de las Islas Caimán administrado por Ayrton Capital y a Waqas Khatri como miembro gestor; las firmas certifican que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no con el fin de cambiar o influir en el control.

ReShape Lifesciencesì� Schedule 13G/Aì—� 따르ë©� Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B ë°� Waqas KhatriëŠ� ê°ê° 발행회사ì� 보통ì£� 80ì£�ì—� 대í•� 실질ì � ì†Œìœ ê¶Œì„ ë³´ê³ í–ˆìŠµë‹ˆë‹¤. 80ì£� í¬ì§€ì…˜ì€ 보유 8ì£�ì™¶Ä ì›ŒëŸ°íŠ� 행사ë¡� 발행 가능한 72ì£�ë¡� 구성ë˜ë©°, 워런íŠ� ê´€ë � 발행 가능한 주ì‹ì€ 9.99%ì� 실질ì � 소유 제한ì� ì ìš©ì� 받습니다. 보유 ë‚´ì—­ì€ 2025ë…� 6ì›� 30ì� 기준으로 ë³´ê³ ë˜ì—ˆìŠµë‹ˆë‹�.

신고서는 í´ëž˜ìŠ� 기준ì� 2,385,960ì£�(1,331,356ì£� 유통 + 1,054,604ì£� 최근 공모ë¡� íŒë§¤)ë¡� 삼고 ê°� ë³´ê³ ìžëŠ” 해당 í´ëž˜ìŠ¤ì˜ 0.003%ë¥� 보유하는 것으ë¡� 기재합니ë‹�. 보고당사ìžì—ëŠ� Ayrton Capitalì� 운용하는 ì¼€ì´ë§¨ì œë„ 펀드왶� 관리회ì›ì¸ Waqas Khatriê°€ í¬í•¨ë˜ë©°, ì„œëª…ì€ ì¦ê¶Œì� 통ìƒì ì¸ ì˜ì—…과정ì—서 ì·¨ë“ë˜ì–´ 보유ë˜ê³  있으ë©� 지배권ì� 변경하거나 ì˜í–¥ë ¥ì„ 행사하려ëŠ� 목ì ì� 아님ì� 확ì¸í•©ë‹ˆë‹�.

ReShape Lifesciences Schedule 13G/A révèle que Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B et Waqas Khatri déclarent chacun une détention bénéficiaire de 80 actions du capital social de l'émetteur. La position de 80 actions est décrite comme 8 actions détenues plus 72 actions susceptibles d'être émises à l'exercice de warrants, et les actions liées aux warrants sont soumises à un plafond de détention bénéficiaire de 9,99%. Les avoirs sont déclarés au 30 juin 2025.

Le dépôt retient une base de classe de 2 385 960 actions (1 331 356 en circulation plus 1 054 604 actions vendues lors d'une offre récente) et indique que chaque déclarant représente 0,003% de la classe. Les parties déclarantes incluent un fonds des îles Caïmans géré par Ayrton Capital et Waqas Khatri en tant que membre gestionnaire ; les signatures certifient que les titres ont été acquis et sont détenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contrôle.

ReShape Lifesciences Schedule 13G/A legt offen, dass Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B und Waqas Khatri jeweils eine wirtschaftliche Beteiligung von 80 Aktien an den Stammaktien des Emittenten melden. Die 80-Aktien-Position wird als 8 gehaltene Aktien plus 72 bei Ausübung von Warrants auszugebende Aktien beschrieben, und die durch Warrants auszugebenden Aktien unterliegen einer 9,99%igen Beschränkung der wirtschaftlichen Beteiligung. Die Bestände werden zum 30. Juni 2025 gemeldet.

Die Einreichung verwendet eine Klassengrundlage von 2.385.960 Aktien (1.331.356 ausstehend plus 1.054.604 in einer kürzlich durchgeführten Platzierung verkaufte Aktien) und gibt an, dass jede meldende Person 0,003% der Klasse repräsentiert. Zu den meldenden Parteien gehört ein Fonds auf den Kaimaninseln, der von Ayrton Capital verwaltet wird, sowie Waqas Khatri als Managing Member; die Unterschriften bestätigen, dass die Wertpapiere im normalen Geschäftsverkehr erworben und gehalten wurden und nicht dazu dienen, die Kontrolle zu verändern oder zu beeinflussen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Small disclosed position � 80 shares (0.003%), mainly warrant exposure; filing is informational and not material to control.

The filing reports identical beneficial ownership across three related reporting persons: 80 shares each, comprised of 8 shares held and 72 shares issuable on warrants. The reported percentage of 0.003% is calculated on a class base of 2,385,960 shares. The presence of a 9.99% beneficial ownership blocker on the warrants is noted. From a securities-impact perspective this disclosure documents positions but does not reflect a material ownership stake or trigger reporting thresholds that typically affect market perception or control.

TL;DR: Filing documents ownership and ordinary-course acquisition; it contains no signs of a challenge to governance or control intent.

The statement includes representations that the securities were acquired and are held in the ordinary course of business and not to influence control. Signatories include the investment manager and the managing member, and the report identifies the Cayman fund and its Delaware investment manager. Given the reported 0.003% ownership and the limited share count, the disclosure is routine from a governance standpoint and does not indicate activism or control efforts.

ReShape Lifesciences Schedule 13G/A indica che Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B e Waqas Khatri dichiarano ciascuno una detenzione beneficiaria di 80 azioni del capitale sociale dell'emittente. La posizione di 80 azioni è descritta come 8 azioni detenute ±è¾±Ã¹ 72 azioni emettibili all'esercizio dei warrant, e le azioni emettibili in relazione ai warrant sono soggette a un blocco di partecipazione del 9,99%. Le partecipazioni sono riportate al 30 giugno 2025.

La comunicazione utilizza una base di classe di 2.385.960 azioni (1.331.356 in circolazione ±è¾±Ã¹ 1.054.604 azioni vendute in un'offerta recente) e segnala che ogni soggetto dichiarante rappresenta il 0,003% della classe. Le parti segnalanti includono un fondo delle Isole Cayman gestito da Ayrton Capital e Waqas Khatri in qualità di membro amministratore; le firme certificano che i titoli sono stati acquisiti e sono detenuti nell'ordinario corso dell'attività e non con l'intento di modificare o influenzare il controllo.

ReShape Lifesciences Schedule 13G/A revela que Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B y Waqas Khatri informan cada uno una titularidad beneficiaria de 80 acciones del capital social del emisor. La posición de 80 acciones se describe como 8 acciones en posesión ³¾Ã¡²õ 72 acciones susceptibles de emitirse al ejercerse warrants, y las acciones emitibles vinculadas a los warrants están sujetas a un bloqueo de titularidad beneficiaria del 9,99%. Las tenencias se comunican al 30 de junio de 2025.

La presentación utiliza una base de clase de 2.385.960 acciones (1.331.356 en circulación ³¾Ã¡²õ 1.054.604 acciones vendidas en una oferta reciente) e informa que cada declarante representa el 0,003% de la clase. Las partes informantes incluyen un fondo de las Islas Caimán administrado por Ayrton Capital y a Waqas Khatri como miembro gestor; las firmas certifican que los valores fueron adquiridos y se mantienen en el curso ordinario del negocio y no con el fin de cambiar o influir en el control.

ReShape Lifesciencesì� Schedule 13G/Aì—� 따르ë©� Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B ë°� Waqas KhatriëŠ� ê°ê° 발행회사ì� 보통ì£� 80ì£�ì—� 대í•� 실질ì � ì†Œìœ ê¶Œì„ ë³´ê³ í–ˆìŠµë‹ˆë‹¤. 80ì£� í¬ì§€ì…˜ì€ 보유 8ì£�ì™¶Ä ì›ŒëŸ°íŠ� 행사ë¡� 발행 가능한 72ì£�ë¡� 구성ë˜ë©°, 워런íŠ� ê´€ë � 발행 가능한 주ì‹ì€ 9.99%ì� 실질ì � 소유 제한ì� ì ìš©ì� 받습니다. 보유 ë‚´ì—­ì€ 2025ë…� 6ì›� 30ì� 기준으로 ë³´ê³ ë˜ì—ˆìŠµë‹ˆë‹�.

신고서는 í´ëž˜ìŠ� 기준ì� 2,385,960ì£�(1,331,356ì£� 유통 + 1,054,604ì£� 최근 공모ë¡� íŒë§¤)ë¡� 삼고 ê°� ë³´ê³ ìžëŠ” 해당 í´ëž˜ìŠ¤ì˜ 0.003%ë¥� 보유하는 것으ë¡� 기재합니ë‹�. 보고당사ìžì—ëŠ� Ayrton Capitalì� 운용하는 ì¼€ì´ë§¨ì œë„ 펀드왶� 관리회ì›ì¸ Waqas Khatriê°€ í¬í•¨ë˜ë©°, ì„œëª…ì€ ì¦ê¶Œì� 통ìƒì ì¸ ì˜ì—…과정ì—서 ì·¨ë“ë˜ì–´ 보유ë˜ê³  있으ë©� 지배권ì� 변경하거나 ì˜í–¥ë ¥ì„ 행사하려ëŠ� 목ì ì� 아님ì� 확ì¸í•©ë‹ˆë‹�.

ReShape Lifesciences Schedule 13G/A révèle que Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B et Waqas Khatri déclarent chacun une détention bénéficiaire de 80 actions du capital social de l'émetteur. La position de 80 actions est décrite comme 8 actions détenues plus 72 actions susceptibles d'être émises à l'exercice de warrants, et les actions liées aux warrants sont soumises à un plafond de détention bénéficiaire de 9,99%. Les avoirs sont déclarés au 30 juin 2025.

Le dépôt retient une base de classe de 2 385 960 actions (1 331 356 en circulation plus 1 054 604 actions vendues lors d'une offre récente) et indique que chaque déclarant représente 0,003% de la classe. Les parties déclarantes incluent un fonds des îles Caïmans géré par Ayrton Capital et Waqas Khatri en tant que membre gestionnaire ; les signatures certifient que les titres ont été acquis et sont détenus dans le cours normal des affaires et non dans le but de modifier ou d'influencer le contrôle.

ReShape Lifesciences Schedule 13G/A legt offen, dass Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B und Waqas Khatri jeweils eine wirtschaftliche Beteiligung von 80 Aktien an den Stammaktien des Emittenten melden. Die 80-Aktien-Position wird als 8 gehaltene Aktien plus 72 bei Ausübung von Warrants auszugebende Aktien beschrieben, und die durch Warrants auszugebenden Aktien unterliegen einer 9,99%igen Beschränkung der wirtschaftlichen Beteiligung. Die Bestände werden zum 30. Juni 2025 gemeldet.

Die Einreichung verwendet eine Klassengrundlage von 2.385.960 Aktien (1.331.356 ausstehend plus 1.054.604 in einer kürzlich durchgeführten Platzierung verkaufte Aktien) und gibt an, dass jede meldende Person 0,003% der Klasse repräsentiert. Zu den meldenden Parteien gehört ein Fonds auf den Kaimaninseln, der von Ayrton Capital verwaltet wird, sowie Waqas Khatri als Managing Member; die Unterschriften bestätigen, dass die Wertpapiere im normalen Geschäftsverkehr erworben und gehalten wurden und nicht dazu dienen, die Kontrolle zu verändern oder zu beeinflussen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Ayrton Capital LLC
Signature:/s/ Waqas Khatri
Name/Title:Waqas Khatri / Managing Member
Date:08/13/2025
Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B
Signature:/s/ Waqas Khatri
Name/Title:Waqas Khatri / Director
Date:08/13/2025
Waqas Khatri
Signature:/s/ Waqas Khatri
Name/Title:Waqas Khatri
Date:08/13/2025

FAQ

How many RSLS shares do Ayrton Capital, Alto Opportunity Master Fund and Waqas Khatri report?

Each reporting person reports beneficial ownership of 80 shares of ReShape Lifesciences common stock.

What is the composition of the 80 shares reported in the RSLS filing?

The 80 shares consist of 8 shares held and 72 shares issuable upon exercise of certain warrants.

What percentage of RSLS does the 80-share position represent?

The filing reports the position as 0.003% of the class based on 2,385,960 shares used for the calculation.

Are the warrant issuable shares subject to any ownership restrictions?

Yes, the filing states the shares issuable on exercise of the warrants are subject to a 9.99% beneficial ownership blocker.

Does the filing indicate an intent to influence control of RSLS?

No. The certification states the securities were acquired and are held in the ordinary course of business and not to change or influence control.

What class of security and CUSIP are reported in this filing for RSLS?

The filing covers Common stock, $0.001 par value of ReShape Lifesciences with CUSIP 76090R408.
Reshape Lifesciences Inc.

NASDAQ:RSLS

RSLS Rankings

RSLS Latest News

RSLS Latest SEC Filings

RSLS Stock Data

4.49M
2.13M
10.63%
0.73%
7.77%
Medical Devices
Pharmaceutical Preparations
United States
SAN CLEMENTE